Research programme: chimeric antigen receptor T cell therapeutics - City of Hope National Medical Center/Mustang Bio

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - City of Hope National Medical Center/Mustang Bio

Alternative Names: CAR-T cells - Coronado/City of Hope; CAR-T cells - Mustang Bio

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator City of Hope National Medical Center
  • Class CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 13 Apr 2015 Early research in Cancer (Refractory metastatic disease) in USA (unspecified route)
  • 19 Mar 2015 Coronado Biosciences enters into a collaboration with City of Hope National Medical Center for development and commercialisation of proprietary chimeric antigen receptor through formation of Mustang Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top